for pregnant women suffering from symptoms of significant hyperacidity and GERD The number of patients was a limiting factor and more studies need to be done to establish the therapeutic benefits of combination antacids in pregnant population.
OBJECTIVES: Adherence with 5-aminosalicylic acid (5-ASA) treatments has been shown to be associated with a reduction in disease relapses in UC patients. The aim of this budget impact analysis was to explore and quantify how adherence with individual 5-ASA treatments may impact direct medical costs, through prevented relapses, in the UK. METHODS: A 1-year decision analytic budget impact model was developed to combine data from a UK-based adherence study of 5-ASA treatments with a chart review study on UC costs by relapse status in the UK. The model calculates the rates of disease relapses, remissions, and associated costs, based on adherence rates of each 5-ASA medication. The model also allows running simulations of relative changes in treatment utilization to show the associated budget impact from the perspective of the National Health Service (NHS 27.8% for balsalazide) were associated with lower hospitalization rates (6.6%; 7.3%; 7.7%; 8.1%; 8.3%; 8.3%; and 8.5%, respectively), lower annual hospitalization costs (£330; £365; £383; £404; £414; £414; and £422, respectively), and lower other medical costs, excluding 5-ASAs (£282; £292; £298; £305; £307; £308; and £310, respectively). The model showed that a hypothetical move from the current utilization mix of 5-ASA treatments to the 5-ASA with the highest adherence rate could save the NHS approximately £92,800 annually per 1,000 UC patients. CONCLUSIONS: As non-adherence in UC is associated with costly medical resource utilization, significant cost-offsets could be achieved within the NHS by favoring the 5-ASA treatment with the highest adherence rate. Charta fondation, milano, Italy, 5 Federico II University of Naples, Naples, Italy OBJECTIVES: Inhibitor development is one of the most important and expensive adverse event in patients with severe hemophilia A. A different incidence between second or third generation FVIII determine different resource consumption in long term therapy. The Pass study aimed to assess the break-even point in patients treated with ADVATE® or with another second or third generation (FVIII X), considering effects on direct medical cost attributable to different inhibitors development. METHODS: A model based on Oldenburg 2010 study population characteristic( 348 Pre Treated Patients; FVIII Յ2%; no previous inhibitor stories) was developed comparing costs generate from ADAVATE® treatment vs "FVIII X". We considered a time horizon of 5 years and the National Health System's (NHS) point of view. In order to assess the validity of the breakeven point estimate, a sensitivity analysis was conducted modifying the percentages of patients allocated to prophylaxis or on demand regimen. RESULTS: According to model results the overall cost during 5 years was: 243,966,787.44€ for ADAVATE® treatment and 223,402,102.06€ for "FVIII X" treatment. To gain the break-even point between ADAVATE® and "FVIII X", the number of patients who should develop inhibitors was 4.98(1.43%) in 5 years. If all patients were allocated to prophylaxis regimen, to gain the break-even point the number of patients who should develop inhibitors was 9.68(2.78%). On the other hand for on demand treatment it should be 1.29(0.37%). CONCLUSIONS: Considering the high cost generated by inhibitor development and the lack of direct comparing studies in scientific literature, the Pass Study provided interesting information for decision makers in order to manage properly patients care. Inhibitor development should be more considered during decision process, as an expensive adverse event in hemophilic A patients treatment. A direct comparing study is necessary to obtain more consistent results.
PGI8 SECOND AND THIRD GENERATION FVIII TREATMENT RESOURCES CONSUMPTION BREAK-EVEN POINT: THE PASS STUDY RESULTS

PGI9 PHARMACOECONOMIC EVALUATION OF ANTYHELICOBACTER THERAPY OF ULCERS DUODENUM IN UKRAINE
OBJECTIVES: Disease related malnutrition (DRM) and its risk are still highly prevalent in some patient populations, depending on patients' diagnoses and age, setting and assessment tools used. DRM is associated with increased morbidity and mortality, decreased QOL, frequent hospitalizations and increased health care costs. Moreover, the economic and human costs of malnutrition are avoidable. The purpose of the study is to estimate cost of DRM in Croatia by assessing direct costs related to hospitalizations, drug consumption, outpatient care in selected illnesses (IBD, gastric and lung cancers, chronic renal impairment and COPB). Selection was based on most evidential relations and available data. Secondary objective was to calculate and compare the total and per capita medical expenditures for people with DRM and identify cost saving potential. METHODS: Prevalence-based cost-ofillness methodology was used to estimate the direct costs (hospital, drugs, physician and institutional care) and indirect costs (sickness leave) associated with disease complications related to DRM, as well as patient monitoring and drugs. The analysis was oriented primary to adult patients receiving hospital in-patient, outpatient or specified community health-care services. RESULTS: The annual cost associated with adult malnourished patients in selected illnesses is estimated at over 100€ million. Most of this cost are in acute hospital (infections, rehospitalizations) and home care with nutrition support estimated to Ͻ10 % of spend. This cost is substantial, inclining to rise with population aging (older people have increased DRM risk). So far there has been no attention focused on the economic burden associated with DRM in Croatia or the potential for savings arising from improved detection and treatment of those at risk. CONCLUSIONS: Screening of malnutrition as well as better nourishing therapies, in sense of better adherence to guidelines, would not only evade mortality and morbidity, but save substantial resources.
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